2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Pathology, Treatment Considerations, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Non-Biological Therapies, Palliative Care, Biological Processes, Pathogenesis, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Value, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, MDS, MPN, Clinical Research, Clinical Trials, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

4422 A DRIVE score assessment of population representation of the evidence supporting the 2025 ASH AML guideline

Maya Nicole Birhiray, M.S., Sam Ranger, MS2, Abbey Suess, BS3, Ruemu Ejedafeta Birhiray, MD4
1 Indiana University School of Medicine, Indianapolis, Indiana, United States, Indy Hematology Education, Carmel, Indiana, United States
2 Indy Hematology Education, Carmel, Indiana, United States
3 Indy Hematology Education, Carmel, Indiana, United States
4 Hematology Oncology of Indiana PC, Indianapolis, Indiana, United States, Indy Hematology Education, Carmel, Indiana, United States, Wood College of Osteopathic Medicine, Indianapolis, Indiana, United States

Introduction: The American Society of Hematology (ASH) 2025 guidelines for the management of newly diagnosed Acute Myeloid Leukemia (AML) in older adults provides evidence-based recommendations intended to standardize and improve clinical care. The imprimatur of major medical societies further reinforces confidence in these recommendations. These guidelines intend to promote uniformity of care for older patients with AML, yet there is still a critical need for clinical research that more accurately reflects the diversity of patient epidemiology.?While guideline panels rigorously evaluate efficacy, safety, and quality of evidence, the representativeness of the populations enrolled in the supporting clinical trials is not routinely assessed. The DRIVE ranking score assesses representation in clinical trials based on disease epidemiology (Birhiray & Birhiray, 2023). A DRIVE Score of 3 or higher is the benchmark for clinical excellence and relevance based on racial representation. An analysis of the 2025 ASH AML guidelines using the DRIVE score evaluates the generalizability and transportability of the referenced clinical trials.? 

Methods: All references reviewed and cited are from the ASH 2025 guidelines for newly diagnosed AML in older adults. Primary interventional clinical trial reports were identified from the guidelines’ reference list. Race and ethnicity data were extracted from the original publications and confirmed with demographic information reported in the National Cancer Institute Clinical Trials Reporting Program (NCTRP) results database when necessary. Trials conducted exclusively outside the United States were excluded because DRIVE scoring is based on comparison with the U.S. disease population. Eligible studies were independently scored using the validated DRIVE methodology.? 

Results: Of the 150 references supporting the ASH 2025 AML guidelines, 41 were primary interventional clinical trial reports. Twenty-one trials (51.2%) were conducted exclusively outside the United States and were excluded. The remaining 20 studies evaluated contemporary AML therapies, including hypomethylating agents, venetoclax-based combinations, targeted inhibitors, and intensive chemotherapy. DRIVE scores were as follows: 0x (n=4), 0* (n=9), 0 (n=1), 1 (n=5), and 3 (n=1). Overall, only one trial (5%) achieved the DRIVE threshold for clinical trial excellence, while 19 (95%) failed to meet DRIVE standards.?AML prevalence across ethnicities is similar; however, patient outcome data reveals consistent and significant racial disparities which are not considered in the underlying data for the AML guidelines (Loeb et al., 2025).  

Conclusion: ?Among U.S.-based interventional trials in AML supporting the 2025 ASH guideline for older adults with newly diagnosed AML, only one achieved the predefined DRIVE benchmark for population representation and clinical trial excellence. These findings highlight an important opportunity to complement traditional assessments of efficacy, safety, and evidence quality usually ranked by strength-based levels with standardized evaluations of population representativeness during guideline development. Greater transparency and reporting of data regarding the representativeness of supporting evidence and broader inclusion of historically underrepresented populations may strengthen the transportability of guideline recommendations across the diverse U.S. AML population. Consistent with our previously described concept of data hallucination, extrapolating findings from inadequately representative study populations to broader patient populations may introduce unsupported assumptions regarding treatment effectiveness and contribute to persistent disparities in clinical outcomes. Incorporating standardized assessments (e.g. DRIVE SCORE) of population representation into future clinical trial evaluation and guideline development may strengthen the evidentiary foundation of clinical practice recommendations, with transparency and improve confidence in their applicability to all patients for whom the guidelines are intended in clinical practice.

Maya Nicole Birhiray, M.S.: No relevant conflicts of interest to declare.